When I started MAPS in 1986, the FDA was still blocking all research with psychedelics. MAPS had to try, though we might never succeed, to gather sufficient data about the safety and efficacy of MDMA-assisted therapy to seek approval for prescription use.
As it has turned out, it took 37-and-a-half- years to gather the necessary data to seek approval! All the effort and time have been totally worth it for the progress that we have seen in our research and the millions of people we hope to help through the public-benefit pharmaceutical model if the FDA does approve the treatment.”
Originally appearing here (Archived)
